Loading
ARID1A (AT-rich interactive domain-containing protein 1A) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Colorectal cancer, Endometrial cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Binds DNA non-specifically. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. Location: Nucleus (UniProt). Locus 1p36.11 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Gallbladder cancer | 13-25% | Mutation (loss of function) | 13% of 85 (Javle 2016); mutation in 50 of 244 samples, 20.5%, in cBioPortal gbc_mskcc_2022 and 26 of 103, 25.2%, in gbc_msk_2018; significantly lower in 376 Indian patients (Suryavanshi 2025) and absent from the 11 Japanese tumours in Narayan 2019; among the 32 significantly mutated biliary genes in Wardell 2018. | doi.org |
| Colorectal cancer | 9-13% | Inactivating mutation | cBioPortal: 912 of 7,237, 12.6%, in crc_msk_2026; 104 of 1,134, 9.2%, in crc_msk_2017; 136 of 1,516, 9.0%, in crc_eo_2020; 58 of 534, 10.9%, in coadread_tcga_pan_can_atlas_2018; 67 of 619, 10.8%, in coadread_dfci_2016. KMT2D reads 805 of 7,237 and KMT2C 605 of 7,237 in the same study. | cBioPortal (TCGA) |
| Pancreatic ductal adenocarcinoma | 5-9% | Inactivating mutation (SWI/SNF and chromatin genes) | cBioPortal: 204 of 2,336, 8.7%, in pdac_msk_2024; 35 of 395, 8.9%, in pancreas_msk_2024; 29 of 383, 7.6%, in paad_qcmg_uq_2016; 9 of 179, 5.0%, in paad_tcga_pan_can_atlas_2018; 8 of 140 in paad_cptac_2021; 7 of 109 in paad_utsw_2015. KMT2C 73, KMT2D 100, SMARCA4 52, PBRM1 32 and ARID2 30 of 2,336 in the same study. Chromatin-regulating gene mutations (MLL, MLL2, MLL3, ARID1A) in 20% of 101 patients were associated with improved survival (Sausen 2015); ARID1A was a significantly mutated gene in 99 exomes (Biankin 2012) and a recurrent gene in TCGA (Cancer Genome Atlas 2017). | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"ARID1A" OR ABSTRACT:"ARID1A" OR TITLE:"AT-rich interaction domain 1A" OR ABSTRACT:"AT-rich interaction domain 1A" OR TITLE:"AT-rich interactive domain-containing protein 1A" OR ABSTRACT:"AT-rich interactive domain-containing protein 1A" OR TITLE:"B120" OR ABSTRACT:"B120" OR TITLE:"P270" OR ABSTRACT:"P270" OR TITLE:"C10rf4" OR ABSTRACT:"C10rf4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARID1A, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/arid1a.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/arid1a.json. Licence CC BY-NC 4.0.